Featured Articles
-
Your Approach To USP <382> For Your Drug Product Packaging
The USP requirements for elastomeric components of container closure systems used for parenteral products are changing. Explore the implications for vial, syringe, and cartridge container closure systems.
-
Container Closure Integrity Evaluation For Cell And Gene Therapies
With the growth of gene and cell therapies, there is an increased need to characterize container closure systems at the low temperatures experienced during their lifecycles.
-
Is It Ever Too Soon To Start Your Extractables And Leachables Assessment?
Learn what you need to know about planning for your extractables and leachables testing programs to mitigate delays to your drug development timelines.
-
Successful Industrialization Requires Solid Foundations
Learn how choosing the appropriate quality of containment systems from the outset is critical to the successful industrialisation of an injectable drug product and review some of the associated challenges.
-
USP <382>: Think Systems, Not Components
This blog focuses on the application of USP <382> prescribed testing to cartridges and syringes from a mechanical testing perspective.
-
Selecting Container Closure Components: A Data-Driven Approach To CCI
Discover an efficient, data-driven process that employs innovative methods to accelerate the selection of a closure containment system that meets the requirements of the modern regulatory landscape.
-
Plan For Your Extractables And Leachables Studies To Meet Submission Timelines
Demonstrating the compatibility of any material in contact with drug product throughout its lifecycle (manufacture, containment, and delivery) is a necessity for a regulatory submission.
-
Demystifying Performance Testing: Strategies To Qualify Combination Products
Explore applicable regulations and guidances, and performance risks identified using failure modes and effects analyses (FMEA) and failure cause mapping analyses.
-
The Path To Commercialization For Wearable Drug Delivery Devices
Explore the evolution of the wearable drug delivery market, including the route to commercialization and the challenges faced.
-
Early Decisions To De-Risk The Transition To Combination Products
The injectable product development landscape is changing, and the pressure to accelerate timelines remains constant. What can you do to overcome all the uncertainty and risk?